Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
One or more serious adverse events · cognitively healthy people in midlife
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at end of treatment · women with PMS
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with placebo (low certainty).
1 finding from 1 review
Adverse events: hospital admission · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
GRADE not reported
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Incidence/nature of adverse events · adults with neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Severe adverse events: neutropenia · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: neutropenia (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Any adverse events Up to 12 weeks' · Patients with acute low‐back pain
Paracetamol showed no clear difference in any adverse events Up to 12 weeks' compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
People with serious adverse events · people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Other adverse events Non‐mortality · adult survivors of critical illness
1 finding from 1 review
Intervention not reported
Adverse events: arthralgia/myalgia · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: arthralgia/myalgia (very low certainty).
1 finding from 1 review
Any adverse events or complications · people with liver metastases
1 finding from 1 review
Any adverse events or complications · people with liver metastases
It is very uncertain whether microwave coagulation changes any adverse events or complications compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Any adverse events or complications · people with liver metastases
1 finding from 1 review
Serious adverse events (at 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review